Abstract
Background
In the United States, the overall survival rates for gastric adenocarcinoma have remained low, with surgical resection as the only therapy for many patients. Given the advances in multimodality treatment and the development of guidelines recommending adequate lymph node evaluation, the authors determined whether overall survival rates for patients with gastric adenocarcinoma have increased in the United States.
Methods
The study used the Surveillance Epidemiology and End Results (SEER) database to examine overall survival for patients with the diagnosis of gastric adenocarcinoma between 1988 and 2013. The study cohort was divided into five periods: 1988–1992, 1993–1997, 1998–2002, 2003–2007, and 2008–2013. Kaplan–Meier methods and Cox proportional hazards modeling were used to determine the effect that year of diagnosis had on overall survival.
Results
The diagnosis was determined for 13,470 patients between 1988 and 2013. The use of radiation therapy and the proportion of patients who had at least 15 lymph nodes evaluated significantly increased during the study period. Unadjusted Kaplan–Meier estimates demonstrated significantly better survival rates for the patients with a diagnosis of gastric cancer in the later periods (2003–2007 and 2008–2013) than for those in the three earlier periods. In our Cox proportional hazards model, recent period was associated with a significantly lower hazard of 5-year mortality.
Conclusion
This analysis demonstrated for the first time that gastric cancer survival rates have significantly improved in the United States during the past 2 decades. This observation likely reflects improved adherence to cancer treatment guidelines, including adequate lymph node evaluation and delivery of adjuvant treatment more consistently.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol 2015;1:505–27.
Surveillance, Epidemiology, and End Results Program (SEER) Fast Fact Sheets: Stomach Cancer (2016), http://seer.cancer.gov/statfacts/html/stomach.html. Accessed 1 Jul 2016
Macdonald JS, Schnall SF. Adjuvant treatment of gastric cancer. World J Surg 1995;19:221–5.
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.
Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327–33.
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–30.
NCCN Gastric Cancer Panel. NCCN Clinical Practice Guidelines in Oncology, Gastric cancer (2016), https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed 4 Aug 2016
Japanese Gastric Cancer Association, Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer 1998;1:10–24
Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, et al. Trends in incidence, treatment, and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer 2010;46:1101–10.
Ebinger SM, Warschkow R, Tarantino I, Schmied BM, Guller U, Schiesser M. Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis. Gastric Cancer. 2016;19:723–34.
Wang W, Zheng C, Fang C, Li P, Xie J, Lin J, et al. Time trends of clinicopathologic features and surgical treatment for gastric cancer: results from 2 high-volume institutions in southern China. Surgery 2015;158:1590–7.
Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer 1997;80:2333–41.
Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439–49.
American Joint Committee on Cancer Staging Manual. 5th ed. J. B. Lippincott: Philadelphia; 1997
Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US population database. J Clin Oncol 2005;23:7114–24.
Papenfuss WA, Kukar M, Oxenberg J, Attwood K, Nurkin S, Malhotra U, et al. Morbidity and mortality associated with gastrectomy for gastric cancer. Ann Surg Oncol 2014;21:3008–14.
Bartlett EK, Roses RE, Kelz RR, Drebin JA, Fraker DL, Karakousis GC. Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database. Surgery 2014;156:298–304.
da Costa WL Jr, Coimbra FJ, Ribeiro HS, Diniz AL, de Godoy AL, de Farias IC, et al. Total gastrectomy for gastric cancer: an analysis of postoperative and long-term outcomes through time: results of 413 consecutive cases in a single cancer center. Ann Surg Oncol 2015;22:750–7.
Disclosures
The authors have no financial disclosures.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Arsoniadis, E.G., Marmor, S., Diep, G.K. et al. Survival Rates for Patients with Resected Gastric Adenocarcinoma Finally have Increased in the United States. Ann Surg Oncol 24, 3361–3367 (2017). https://doi.org/10.1245/s10434-017-5992-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-017-5992-2